科创生物医药ETF(588250)涨近2%冲击3连涨，机构：持续关注创新药进展

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) has seen a strong increase of 1.80%, with notable gains from stocks such as Xiangyu Medical (688626) up 7.27% and Microelectrophysiology (688351) also up 7.27% [1] - The Sci-Tech Biopharmaceutical ETF (588250) rose by 1.78%, marking its third consecutive increase, with the latest price at 1.03 yuan. Over the past month, this ETF has ranked first in its category for growth [1] - The upcoming annual American Society of Clinical Oncology (ASCO) conference is expected to enhance the outlook for innovative drugs, as Chinese experts are set to present at the event, potentially boosting the industry's sentiment [1] Group 2 - Institutions believe that the head-to-head comparison of Kangfang Biopharma's Ivosidenib shows strong positive results, reflecting the company's strength and potentially accelerating competition among similar innovative drugs [2] - The Sci-Tech Biopharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in biopharmaceuticals and related fields, representing the overall performance of the sector [2] - As of March 31, 2025, the top ten weighted stocks in the Sci-Tech Biopharmaceutical Index account for 51.35% of the index, with companies like United Imaging Healthcare (688271) and BeiGene (688235) among the leaders [2]